OnCo

Create your OnCo account

One account keeps your watchlist, saved views and cancer choice in sync across your devices, and lets OnCo alert you when a trial or treatment you follow changes. No password: we email you a sign-in link.

Account creation is being switched on. Until then, press Watch on any page and your list stays in this browser.

Living with cancer· Appointment prep

Appointment sheet: Secondary and therapy-related acute myeloid leukaemia

One page to bring and write on: your details, the questions for Secondary and therapy-related acute myeloid leukaemia plus your own, the words you may hear, what to bring, the treatments the standard of care names, and room for the answers and agreed next steps. What you type stays in this browser. Print it or save it as a PDF. New to all this? Start with the first 60 days. Orientation, not medical advice.

Tick the questions to print

All of this cancer's questions start ticked. Untick what does not apply; ticks are kept in this browser. .

Your own questions

Shared with the prep pack, so questions you add there appear here too.

Print or save as PDF

Use (or Ctrl+P, Cmd+P on a Mac). To keep a copy, choose Save as PDF as the destination in the print dialog. Only the sheet prints; the controls stay on screen. Your typed notes print where you typed them; empty fields print as ruled lines to write on.

Appointment sheet

Secondary and therapy-related acute myeloid leukaemia

Prepared with OnCo (onco.cc/prep/aml-secondary/). Orientation, not medical advice; your team knows your case.

My details

Name
Date of appointment
Hospital and clinician
Who is coming with me

What I know, what is unclear, changes to discuss

Saved in this browser
What I know so far
What is unclear to me
Changes since last time

My questions

17 on the sheet
Newly diagnosed
  1. 1.What is my exact diagnosis, stage, and grade, and which tests established them?
  2. 2.Which biomarkers have been tested on my tumour (for example TP53 mutation and allelic state, Complex or monosomal karyotype, Myelodysplasia-related mutations, KMT2A rearrangement, Prior clonal haematopoiesis), and what were the results?
  3. 3.Which subtype is my cancer, and does that change the recommended treatment?
  4. 4.Is germline (inherited) genetic testing recommended for me or my family?
Newly diagnosed, fit for intensive chemotherapy, age 60 to 75
  1. 5.For my situation (newly diagnosed, fit for intensive chemotherapy, age 60 to 75), which of the standard options do you recommend and why?
  2. 6.Am I a candidate for CPX-351 (liposomal daunorubicin-cytarabine), Cytarabine + anthracycline ('7+3'), and what side effects should I expect?
  3. 7.How do the results of CPX-351 Study 301 apply to someone like me?
Newly diagnosed, unfit for intensive chemotherapy
  1. 8.For my situation (newly diagnosed, unfit for intensive chemotherapy), which of the standard options do you recommend and why?
  2. 9.Am I a candidate for Venetoclax, Azacitidine, Decitabine, and what side effects should I expect?
  3. 10.How do the results of VIALE-A apply to someone like me?
Consolidation and relapse
  1. 11.For my situation (consolidation and relapse), which of the standard options do you recommend and why?
  2. 12.Am I a candidate for Gilteritinib, Ivosidenib, Revumenib, and what side effects should I expect?
Any stage
  1. 13.Are there clinical trials I could join, for example of CPX-351 (liposomal daunorubicin-cytarabine), Venetoclax, myeloMATCH, Which patients' blood clones will become leukaemia after treatment??
  2. 14.Would a second opinion at a high-volume centre change anything, and can you help arrange it?
  3. 15.What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?
  4. 16.I read that “No regimen produces durable remissions in TP53-mutated AML”. How does that affect my plan?
  5. 17.I read that “Whether CPX-351 helps patients under 60 or those fit enough for transplant regardless of induction”. How does that affect my plan?

The words I may hear

Tests and results to bring

Newly diagnosed, fit for intensive chemotherapy, age 60 to 75: CPX-351 induction (Study 301) followed by allogeneic transplant in remission; 7+3 where CPX-351 is unavailable.

Newly diagnosed, unfit for intensive chemotherapy: Venetoclax plus azacitidine or decitabine; hypomethylating agent alone for TP53-mutated disease where venetoclax adds little; trials.

Biomarker results to ask for: TP53 mutation and allelic state, Complex or monosomal karyotype, Myelodysplasia-related mutations (SRSF2, SF3B1, ASXL1, RUNX1, U2AF1, EZH2, BCOR, STAG2), KMT2A rearrangement, Prior clonal haematopoiesis, ELN 2022 risk group.

Bring copies of scan reports, pathology and blood results, and a list of every medicine and supplement.

The treatments I may be offered

From the standard of care recorded for this cancer; which apply depends on your stage and biomarkers. Ask which the team recommends and why.

Answers and next steps

Saved in this browser
What I was told
Agreed next steps, dates and who to call